Keywords
| 1. | Ma DD, Bell DR. Multidrug resistance and P-glycoprotein expression in human cancer. Aust NZ J Med 1989;19:736-43. ![]() [PUBMED] |
| 2. | Group EBCTC. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67. ![]() |
| 3. | Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen. Ann N Y Acad Sci 2009;1155:99-111. ![]() [PUBMED] |
| 4. | Prost O, Turrel MO, Dahan N, Craveur C, Adessi GL. Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulfate levels in human breast carcinoma. Cancer Res 1984;44:661-4. ![]() [PUBMED] |
| 5. | Selcer KW, Jagannathan S, Li PK. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. J Steroid Biochem Mol Biol 1996;59:83-91. ![]() [PUBMED] |
| 6. | Santer SJ, Feil PD, Santen RJ. In situ oestrogen production via oestrone sulphatase pathway in breast tumours: Relative importance versus the aromatase pathway. J Clin Endocrinol Metab 1984;59:29-33. ![]() |
| 7. | Saito T, Kinoshita S, Fujii T, Bandoh K, Fuse S, Yamauchi Y, et al. Development of novel steroid sulfatase inhibitors: II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats. J Steroid Biochem Mol Biol 2004;88:167-73. ![]() [PUBMED] |
| 8. | Reed MJ, Purohit A. Sulphatase inhibitors: The rationale for the development of a new endocrine therapy. Rev Endocrine-Related Cancer 1993;45:51-62. ![]() |
| 9. | Reed MJ, Lai LC, Owen AM, Singh A, Coldham NG, Purohit A, et al. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res 1990;50:193-6. ![]() [PUBMED] |
| 10. | Mehta RR, Das Gupta TK. Regulation of 17 beta-hydroxysteroid dehydrogenase in a newly-established human breast carcinoma cell line. J Steroid Biochem Mol Biol 1993;46:623-9. ![]() [PUBMED] |
| 11. | Hassanzadeh F. Design and synthesis of inhibitors of steroid sulphatase and 17-beta-hydroxysteroid dehydrogenase as potential agents in the treatment of breast cancer. PhD Thesis. Cardiff, UK: University of Wales; 1996. ![]() |
| 12. | Li PK, Chu GH, Guo JP, Peters A, Selcer KW. Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids 1998;63:425-32. ![]() [PUBMED] |
| 13. | Taguchi Y, Koslowski M, Bodenner DL. Binding of estrogen receptor with estrogen conjugated to bovine serum albumin (BSA). Nucl Recept 2004;2:5. ![]() [PUBMED] |
| 14. | Selcer KW, Hegde PV, Li PK. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-o-sulfamoyl)-N-alkanoyl tyramines. Cancer Res 1997;57:702-7. ![]() [PUBMED] |
| 15. | Laplante Y, Cadot C, Fournier MA, Poirier D. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg Med Chem 2008;16:1849- ![]() |
| 16. | Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C. Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 2007;6:1031- ![]() |
| 17. | Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally M. Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 2004;10:1160-9. ![]() [PUBMED] |